Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Frontiers in Pharmacology|October 14, 2016
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX StudyCarmine D'Aniello, Maria G Vitale, Azzurra Farnesi, et al.
European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
Frontiers in Immunology|July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 studyMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Pageof 15